Reference | Year | BDNF region | Chromosomal position (hg19) | Phenotype | Tissue | Samples | Method | Statistical power |
---|---|---|---|---|---|---|---|---|
Fuchikami et al. | 2011 | Promoter I Promoter IV | chr11:27743473ā27744564 chr11:27722840ā27723980 | Major depression (MDD) | Peripheral blood | 20 MDD, 18 CT | EpiTYPER | CpG8,9ā75.7Ā % CpG76ā54.3Ā % CpG80,81ā79.1Ā % For rest CpGsā>80Ā % |
DāAddario et al. | 2012 | Promoter I | chr11:27744031ā27744193 | Bipolar disorder I, II (BDI, BDII) | Peripheral blood | 49 BD I, 45 BD II, 52 CT | Methylation-specific real-time PCR | BDII vs CTā62.5Ā % Antidep. vs antidep-freeā93Ā % |
DāAddario et al. | 2013 | Promoter I | chr11:27744031ā27744193 | Major depression | Peripheral blood | 41 MDD, 44 CT | Methylation-specific real-time PCR | Methylation level ā83.1Ā % Expression levelā65.9Ā % |
Ikegame et al. | 2013 | Promoter I Promoter IV | chr11:27743390ā27743763 chr11:27722994ā27723372 | Schizophrenia (SCZ) | Peripheral blood | 100 SCZ, 100 CT | Bisulfite pyrosequencing | CpG72ā52.4Ā % |
Perroud et al. | 2013 | Promoter I Promoter IV | chr11:27743862ā27744057 chr11:27723057ā27723293 | Borderline personality disorder (BPD) | Peripheral blood | 115 BPD, 52 CT | High resolution melt analysis | BPD vs CTā100Ā % |
DellāOsso et al. | 2014 | Promoter I | chr11:27744031ā27744194 | Bipolar disorder I, II, major depression | Peripheral blood | 43MDD, 61 BD I, 50 BD II, 44 CT | Methylation-specific real-time PCR | MDD, BDII vs BDI and CTā100Ā % |
Kleimann et al. | 2015 | Promoter I Promoter IV Promoter VI | chr11:27743416ā27744782 (3 regions) chr11:27723103ā27723511 chr11:27722216ā27722863 (2 regions) | Treatment-resistant major depression (electroconvulsive therapy) | Peripheral blood | 11MDD | Direct bisulfite sequencing | Remit. vs non-remit. 4 treatment sessions: 91ā100Ā % |
Chagnon et al. | 2015 | Promoter I Exon III Promoter VI/Exon VI | NS | Anxiety/major depression | Saliva | 19 MDD, 24 CT | Bisulfite pyrosequencing | MDD vs CTā86.3Ā % CT gen. MDD vs CT gen. CTā88.3Ā % |
Keller et al. | 2010 | Promoter IV | chr11:27723126ā27723144 (4 CpG sites) | Major depression, suicide | Brain (Wernicke area) | 44 SU, 33 CT | Bisulfite pyrosequencing, direct bisulfite sequencing, EpiTYPER | CpG1ā98.1Ā % CpG3ā96.3Ā % Average levelā98.3Ā % |
Kordi-Tamandani et al. | 2012 | Promoter IV | NS | Schizophrenia | Peripheral blood | 80 SCZ, 71 CT | Methylation-specific PCR | Methylation levelā99Ā % Expression levelā94Ā % |
Tadic et al. | 2014 | Promoter IV | chr11:27723103ā27723380 | Major depression (antidepressant treatment) | Peripheral blood | 39 MDD | Direct bisulfite sequencing | NA |
Thaler et al. | 2014 | Promoter IV | chr11:27722840ā27723980 | Bulimic nervosa (BN), Borderline personality disorder | Peripheral blood | 64 BN(F), 32 CT | EpiTYPER | BN vs CTāin average for all CpG sitesā99.8Ā % |
Kang et al. | 2013 | Promoter VI | chr11:27721688ā27721823 | Major depressive, suicidal behavior (antidepressant treatment) | Peripheral blood | 108 MDD | Bisulfite pyrosequencing | Previous suicidal attemptā76.7Ā % Suicidal ideation during treatmentā83.6 and 96.6Ā % |
Kang et al. | 2015a | Promoter VI | chr11:27721688ā27721823 | Depression related to breast cancer | Peripheral blood | 74 D, 235 CT | Bisulfite pyrosequencing | D vs CT within 1Ā week and 1Ā year in averageā81.2Ā % |
Kang et al. | 2015b | Promoter VI | chr11:27721688ā27721823 | Late-life depression | Peripheral blood | 101 D, 631 CT | Bisulfite pyrosequencing | D vs CT at baseline and after 2Ā years in averageā97.7Ā % |
Unternaehrer et al. | 2015 | Exon VI | chr11:27721543ā 277221857 | Low maternal care (LC) vs. high maternal care (HC) | Peripheral blood | 45 LC, 40 HC | EpiTYPER | NA |
Mill et al. | 2008 | Promoter IX | chr11:27679911ā27680006 | Schizophrenia, bipolar disorder | Brain (frontal cortex) | 35 SZ, 35 BD, 35 CT | Enriched unmethylated DNA microarray, bisulfite pyrosequencing | Val homozygotes (78) vs Met carries (27)ā100Ā % |